07:49 AM EDT, 08/29/2025 (MT Newswires) -- NeoGenomics ( NEO ) said Friday that a North Carolina district court granted the company's motion for summary judgment that Natera's ( NTRA ) asserted patents are invalid for claiming ineligible subject matter.

The move allows NeoGenomics ( NEO ) to continue to broadly commercialize its RaDaR ST molecular residual disease assay in the US, the company said.

NeoGenomics ( NEO ) shares were up nearly 20% in recent premarket activity, while Natera ( NTRA ) fell 2.4%.